Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Continues to Lighten Debts

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Continues to Lighten Debts

Analysts would eye the upcoming earnings due later this month, while the company is expected to give a lower guidance amid recent developments

Healthcare

Merck & Co., Inc. (NYSE:MRK): Upgraded To Overweight

FDA Lung Cancer Boost For Keytruda Drives Upgrade for Merck by PiperJaffray

Gilead Sciences, Inc. (NASDAQ:GILD) Adds Flexibility to M&A Philosophy

BMO Capital Markets key takeaways after meeting with management

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Would no Longer be Able to Sell Salix to Takeda

Takeda has recently finalized the acquisition of cancer drugmaker ARIAD Pharmaceuticals for $5.2 billion

Valeant Pharmaceuticals Intl Inc: Good Days Might be Ahead for VRX StocK

Valeant's recent divestitures will dramatically reduce its debt and provide management with ample to steer the company toward growth trajectory

Here's Why Valeant Pharmaceuticals Intl, Inc,. (VRX) No Longer Does The Trick For Investors

It won't be wrong to say that the Laval based-company is slowly nearing its end as it continues to sell off business units